A New ATP-Sensitive Potassium Channel Opener Protects the Kidney from Hypertensive Damage in Spontaneously Hypertensive Rats

The effects of iptakalim, a new ATP-sensitive potassium channel opener, were studied in spontaneously hypertensive rats (SHR). Treatment of 12-week-old male SHR (six animals in each group) with iptakalim by gastric lavage at doses of 1, 3, or 9 mg/kg/day for 12 weeks resulted in a lowering of blood pressure. Iptakalim provided significant renoprotection to SHR rats as measured by decreased proteinuria and improved renal function. Histological evidence demonstrated that iptakalim could reverse renal vascular remodeling (of afferent arterioles, arcuate arteries, or interlobular arteries), and improve pathological changes of glomerular, renal interstitial, and glomerular filtration membranes. These effects were accompanied by the decreased circulation and intrarenal concentrations of endothelin 1 and transforming growth factor β1 (TGF-β1), and down-regulated overexpression of genes for ET-1, endothelin-converting enzyme 1, TGF-β1, and the subunits of ATP-sensitive potassium channels (KATP), Kir1.1 and Kir6.1, in the kidney during hypertension. Abnormal expression of matrix components [collagen IV, fibronectin, matrix metalloproteinase 9 (MMP-9) and MMP tissue inhibitor 1 (TIMP-1)] was also significantly reversed by iptakalim. Our results demonstrate that chronic treatment with iptakalim not only reduces blood pressure but also preserves renal structure and function in SHR. In addition to reducing blood pressure, the renoprotective of iptakalim may be involved in inhibiting the circulation and intrarenal concentrations of endothelin 1 and TGF-β1, regulating the expression of KATP genes and correcting MMP-9/TIMP-1 imbalance in renal tissue, which may result in reducing the accumulation of extracellular matrix molecules.

[1]  C. Long,et al.  A New ATP-Sensitive Potassium Channel Opener Reduces Blood Pressure and Reverses Cardiovascular Remodeling in Experimental Hypertension , 2005, Journal of Pharmacology and Experimental Therapeutics.

[2]  G. Hu,et al.  Targeting Ischemic Stroke with a Novel Opener of ATP-Sensitive Potassium Channels in the Brain , 2004, Molecular Pharmacology.

[3]  Hong Wang,et al.  Effects of iptakalim hydrochloride, a novel KATP channel opener, on pulmonary vascular remodeling in hypoxic rats. , 2004, Life sciences.

[4]  Jia Guo.  Selective vasodilating action in small artery and its pharmacological mechanisms of novel antihypertensive drug iptakalim hydrochloride , 2004 .

[5]  V. Petrov,et al.  Association between transforming growth factor-β and hypertension , 2003 .

[6]  M. Lebel,et al.  Endothelin-1 in chronic renal failure and hypertension. , 2003, Canadian journal of physiology and pharmacology.

[7]  Hai Wang.  Pharmacological characteristics of the novel antihypertensive drug, iptakalim hydrochloride, and its molecular mechanisms , 2003 .

[8]  W. Hai.  Effects of Iptakalim Hydrochloride on Hypertensive Vascular Remodeling , 2003 .

[9]  Long Chao.  Study on selective antihypertensive effects of iptakalim hydrochloride , 2003 .

[10]  P. Carmines,et al.  Altered Electromechanical Coupling In The Renal Microvasculature During The Early Stage Of Diabetes Mellitus , 2002, Clinical and experimental pharmacology & physiology.

[11]  K. Griffin,et al.  Long-term renal consequences of hypertension for normal and diseased kidneys , 2002, Current opinion in nephrology and hypertension.

[12]  B. Palmer.  Impaired renal autoregulation: implications for the genesis of hypertension and hypertension-induced renal injury. , 2001, The American journal of the medical sciences.

[13]  F. Ashcroft,et al.  New windows on the mechanism of action of K(ATP) channel openers. , 2000, Trends in pharmacological sciences.

[14]  F. Amenta,et al.  Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats. , 2000, The Journal of pharmacology and experimental therapeutics.

[15]  R. Fallet,et al.  Exaggerated impact of ATP-sensitive K(+) channels on afferent arteriolar diameter in diabetes mellitus. , 2000, Journal of the American Society of Nephrology : JASN.

[16]  S. Klahr,et al.  The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. , 2000, Kidney international. Supplement.

[17]  F. Besnard,et al.  Regulation of ATP-sensitive potassium channel mRNA expression in rat kidney following ischemic injury. , 2000, Biochemical and biophysical research communications.

[18]  K. Tsuchiya,et al.  The attenuated effect of ATP-sensitive K+ channel opener pinacidil on renal haemodynamics in spontaneously hypertensive rats. , 1998, European journal of pharmacology.

[19]  Erwin P. Bottinger,et al.  Biology of TGF-β in knockout and transgenic mouse models , 1997 .

[20]  M. Mulvany,et al.  Effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist, and an endothelin receptor antagonist on renal afferent arteriolar structure. , 1996, Hypertension.

[21]  M. Fujishima,et al.  Impaired action of levcromakalim on ATP-sensitive K+ channels in mesenteric artery cells from spontaneously hypertensive rats. , 1996, Hypertension.

[22]  F. Locatelli,et al.  Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency , 1996 .